Current Cancer Drug Targets

Current Cancer Drug Targets is a Bentham Science journal founded in 2001 that covers all aspects of cancer drug discovery and development, with a current impact factor of 2.5（Current Cancer Drug Targets）是 Bentham Science 出版的期刊，2001 年创刊，覆盖肿瘤药物发现与开发的各个方面，当前影响因子为 2.5。

Scope

• It covers the full spectrum of cancer drug discovery and development, including cellular and molecular biology, genomics, proteomics, metabolomics, medicinal chemistry, pharmacology, toxicology and biochemistry覆盖肿瘤药物发现与开发的全谱，包括细胞与分子生物学、基因组学、蛋白质组学、代谢组学、药物化学、药理学、毒理学与生物化学。
• It focuses on contemporary molecular drug targets in cancer, such as disease-specific proteins, receptors, enzymes and genes聚焦当代癌症分子药物靶点，如疾病特异性蛋白、受体、酶与基因。
• Its scope covers the prevention, diagnosis and treatment of all types of human cancers, including cancer etiology, signal transduction, biomarkers, chemotherapy, hormone therapy, gene therapy, immunotherapy, radiotherapy, stem cells, the tumour environment and metabolism收录范围覆盖各类人类癌症的预防、诊断与治疗，包括肿瘤病因、信号转导、生物标志物、化疗、激素治疗、基因治疗、免疫治疗、放疗、干细胞、肿瘤环境与代谢。
• Article types include review articles, mini-reviews, systematic reviews, research articles, short communications, letters, randomised drug clinical trial studies and case reports文章类型包括综述、小型综述、系统综述、研究论文、短通讯、来信、随机药物临床试验研究与个案报告。
• Single-topic or thematic issues may also be considered亦可考虑单主题或专题期。

History

• It was founded by Bentham Science Publishers in 2001, with volume 1, number 1 appearing in May 2001该刊由 Bentham Science Publishers 于 2001 年创办，第一卷第一期于 2001 年五月出版。^[1]
• Its founding editor-in-chief was John K. Buolamwini, a medicinal chemist working on cancer drug design创刊主编为 John K. Buolamwini，从事肿瘤药物设计的药物化学家。
• It has been published by Bentham Science Publishers throughout, and the DOI prefix has remained unchanged since 2001该刊自始至终由 Bentham Science Publishers 出版，DOI 前缀自 2001 年沿用至今。
• The National Library of Medicine records eleven issues a year from 2019, but recent volumes have run to about twelve to fourteen issues a year and the journal describes itself as monthly美国国家医学图书馆著录 2019 年起每年十一期，但近年每卷约十二至十四期，该刊自述为月刊。
• It remains a subscription journal with a gold open access option and is not fully open access该刊仍为订阅期刊并设金色开放获取选项，并非完全开放获取。

Editors

• The editor-in-chief is Ruiwen Zhang of the University of Houston, whose field is cancer pharmacology and drug toxicology and who works on MDM2 inhibitors现任主编 Ruiwen Zhang，休斯顿大学，研究肿瘤药理学与药物毒理学，专长 MDM2 抑制剂。^[2]
• The co-editor-in-chief is Masayoshi Yamaguchi of the University of Hawaii Cancer Center共同主编为夏威夷大学癌症中心的 Masayoshi Yamaguchi。
• The associate editors are Rajesh Agarwal of the University of Colorado Denver, Nouri Neamati of the University of Michigan and Paul Workman of the Institute of Cancer Research in the United Kingdom副编辑为科罗拉多大学丹佛分校的 Rajesh Agarwal、密歇根大学的 Nouri Neamati 与英国癌症研究所的 Paul Workman。
• A regional editor for North America and two country editors cover Austria and the United States, and seven section editors cover topics from cancer neuroscience to cancer immunotherapy另设一位北美区域编辑与两位国别编辑，分别负责奥地利与美国；七位栏目编辑覆盖从肿瘤神经科学到肿瘤免疫治疗的各方向。
• Peer review is single-blind and checked with a plagiarism-detection service, and submissions are made directly through the publisher's manuscript system同行评审为单盲，并经查重检测，投稿经出版方的稿件系统直接提交。